Executive Insights: How the Covid-19 vaccine rollout changed AstraZeneca’s goals for the future

Executive Insights | Mon 21 Nov | Author – Business & Finance

Executive Insights, in association with KPMG, is an in-conversation content series featuring thought leaders from across the Irish business community. The series explores business strategy and how to navigate the current climate. 


The latest episode of Executive Insights features Shane Doyle, Senior Vice President and Head of Alexion Operations in conversation with James Delahunt, Partner, Sustainable Futures, KPMG in Ireland.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.

They played a major role in the response to the Covid-19 pandemic with the rapid development of a vaccine. AstraZeneca operates in over 100 countries and provides medicines to millions of patients worldwide.

The company was named Business & Finance FDI Company of the month for June 2022. Alexion, AstraZeneca’s Rare Disease group, invested €65 million in biologic manufacturing, research and development across its sites in College Park, Blanchardstown and Monksland Industrial Park, Athlone.

In this episode of Executive Insights, Shane Doyle and James Delahunt discuss the rollout of the Covid-19 vaccine and its impact on Alexion and AstraZeneca’s goals for the future as well as their plan to be carbon negative by 2030.


Business & Finance Awards

The 48th annual Business & Finance Award will take place on December 1st in the Convention Centre, Dublin. You can register your interest for the prestigious event here.


Previous Executive Insights:

John Goulding, Founder & CEO, Workvivo 

Melíosa O’Caoimh, Country Head, Northern Trust Ireland

Mark Roden, CEO & Co-Founder, Ding